This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Boehringer Ingelheim Pharmaceuticals Inc.
Reference
Zhou Z, et al. Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States. The Journal of Rheumatology : 15 Feb 2019. Available from: URL: http://doi.org/10.3899/jrheum.180445
Rights and permissions
About this article
Cite this article
Economic burden of systemic sclerosis substantial in the US. PharmacoEcon Outcomes News 823, 15 (2019). https://doi.org/10.1007/s40274-019-5705-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5705-0